Cidara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Cidara Therapeutics

07/08/2023 23:17

* Cidara Therapeutics Inc  CDTX.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 13 cents per share.
    * Revenue rose 22.5% to $7.61 million from a year ago;
analysts
expected $11.55 million. 
    * Cidara Therapeutics Inc's reported EPS for the quarter was
a
loss of 14 cents​.
    * The mean earnings estimate of analysts had fallen by
about 44.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cidara Therapeutics Inc shares had fallen by 13.6% this
quarter and gained 29.1% so far this year.
    * The company reported a quarterly loss of $12.36 million.
    * Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 10:16 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.13          -0.14          Missed
 Mar. 31 2023      -0.04          0.03           Beat
 Dec. 31 2022      -0.17          -0.19          Missed
 Sep. 30 2022      0.18           0.17           Missed